TNNT2 and cancer: In patients without PE, addition of NT-proBNP [AUC 80.2 (95% CI 75.8–84.6) vs. 76.1 (95% CI 71.3–80.8), N = 412], CRP [AUC 80.0 (95% CI 76.6–83.3) vs. 77.1 (95% CI 73.6–80.7), N = 759), and cTnT [AUC 78.9 (95% CI 75.3–82.5) vs. 77.0 (95% CI 73.3–80.7), N = 718] provided improved predictive performance compared to a model including age, sex, and cancer (P < 0.05 for all comparisons).